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United States
World Health Organization (WHO) identified twenty tropical disease categories as
neglected tropical diseases (NTDs)1. Chagas’ disease (also known as American
trypanosomiasis) and leishmaniasis are two major classes of NTDs. The total number
of mortality, morbidity, and disability attributed each year due to these two categories of
diseases in magnitudes is much higher than the so-called elite diseases like cancer,
diabetes, AIDS, cardiovascular and neurodegenerative diseases. Impoverished
communities around the world are the major victim of NTDs. The development of new
and novel drugs in the battle against Chagas’ disease and leishmaniasis is highly
anticipated. An easy and straightforward on-water green access to synthesize
benzopyrazines is reported. This ultrasound-assisted procedure does not require any
catalyst/support/additive/hazardous solvents and maintains a high atom economy. A
series of eleven benzopyrazines has been synthesized, and most of the synthesized
compounds possess the drug-likeness following Lipinski’s “Rule of 5”. Benzopyrazines 3
and 4 demonstrated moderate leishmanicidal activity against L. mexicana (M378) strain.
The selective lead compound 1 showed good leishmanicidal, and trypanocidal activities
(in vitro) against both L. mexicana (M378) and T. cruzi (NINOA) strains compared to the
standard controls. The in vitro trypanocidal and leishmanicidal activities of the lead
compound 1 have been validated by molecular docking studies against four
biomolecular drug targets viz. T. cruzi histidyl-tRNA synthetase, T. cruzi trans-sialidase,
leishmanial rRNA A-site, and leishmania major N-myristoyl transferase.
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INTRODUCTION
Heterocycles play a significant role in drug discovery research. A
considerable number of the small molecule inhibitors are
heterocyclic compounds. Among various classes of
heterocycles, for example, aza-, oxo-, phospho-,
thioheterocycles; aza- or nitrogen heterocycles are found in
many pharmacologically relevant compounds natural and
synthetic. Benzopyrazine (also known as quinoxaline) is a
fused bicyclic scaffold in which benzene is fused with pyrazine
(Bandyopadhyay and Banik, 2021). A few naturally occurring
antibiotics and nutrients like vitamin B2 contain benzopyrazine
moiety as a core in their structures (Figure 1). This scaffold is
present as the key structural motif in many biologically active
compounds, which includes anticancer (Lee et al., 2012;
Bandyopadhyay et al., 2013; Qi et al., 2018), antibacterial (El-
Attar et al., 2018), antitubercular (Achutha et al., 2013), anti-
ebola (Loughran et al., 2016), antifungal (Carta et al., 2001)
among many others. Consequently, several procedures of
synthesizing benzopyrazines have been reported in the
literature. A few synthetic procedures, reported in the
immediate past, include the synthesis of benzopyrazines under
the catalytic influence of Co3O4 nanocages based nickel catalyst
(Sharma et al., 2021), iron-catalyzed transfer hydrogenative
condensation (Putta et al., 2021), sodium hydroxide-mediated
hydrogen-transfer (Wang et al., 2021), as well as the uses of
tungstophosphoric acid-support (Kumaresan et al., 2020), and
Co-based nanocatalyst (Panja et al., 2020).
On the other hand, the World Health Organization (WHO)
identified twenty tropical disease categories as neglected tropical
diseases (NTDs). In general, the population below the poverty
line are the primary sufferers of NTDs. Every year millions of
people from 149 countries worldwide are being infected by NTDs
that cause the waste of billions of dollars and a loss of thousands
of lives. Based on the mortality and morbidity rates, Chagas’
disease (named after the Latin American physician Carlos
Chagas, also known as American trypanosomiasis) and
leishmaniasis are two major categories of NTDs that demand
immediate attention from the global community (Maheshwari
and Bandyopadhyay, 2021). We report herein an ultrasound-
assisted on-water green synthesis of diversely substituted
benzopyrazine derivatives (Scheme 1) and subsequent in vitro
trypanocidal and leishmanicidal evaluation of these compounds.
Further, we hypothesize that the biological (trypanocidal and
leishmanicidal) activity is due to the interaction and subsequent
inhibition of the protozoal proteins responsible for these diseases.




We determined the melting points of the final products by a
digital melting point apparatus (DigiMelt MPA 160 by SRS).
Elemental (CHN) analyses were carried out by a PerkinElmer
2,400 Series II elemental analyzer, their results were found to be in
good agreement (±0.5%) with the calculated values. Sonication
was performed with the UP200St (200W, 26kHz) ultra-sonicator
(Hielscher Ultrasonics GmbH, Germany). FT-IR spectra were
recorded on a Bruker Alpha modular Platinum-ATR FT-IR
spectrometer with OPUS software, using the samples directly
FIGURE 1 | Representative examples of naturally occurring bioactive benzopyrazines.
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(neat) without making pallets. 1HNMR (600 MHz) and 13CNMR
(150 MHz) spectra were obtained at room temperature with
Bruker superconducting Ultrashield Plus 600 MHz NMR
spectrometer with central field 14.09 T, coil inductance
89.1 Hz, and magnetic energy 1,127.2 kJ using CDCl3 or d6-
DMSO as solvent. Chemicals were purchased from Sigma-
Aldrich, Inc. (St. Louis, MO) and VWR International
(Missouri, TX). Solvents were purchased from Fisher Scientific
International Inc. (Pittsburgh, PA) throughout the investigation.
General Procedure for the Synthesis of
Benzopyrazines
In a general procedure of this on-water reaction, ortho-diamine and
dicarbonyl compounds were mixed (1:1M ratio) in a hard glass test
tube, and 1ml tap water was added to the reaction mixture. In a
model reaction, 1ml water was taken in a hard glass test tube, and
1mmol of o-phenylene diamine (108mg) and 1mmol of
phenylglyoxal hydrate (134mg) were added into the test tube. The
ultrasonic probewas inserted into the test tube (reactionmixture), and
the mixture was sonicated. The reaction was monitored by thin-layer
chromatography (TLC) every after 1minute. The most intense TLC
spot was seen after 3minutes. Further sonication did not increase the
intensity of the product spot; rather, it reduced the product and
generated gummy material. Initially, the reaction was carried out in
deionized water, but no significant change in yield was observed
compared to tap water. At the end of the reaction, the product looked
like a chunk, and it was not soluble in water. Consequently, the
product was extracted with 9ml (3 × 3mL) of ethyl acetate. The
organic layer was dried over sodium sulfate and concentrated by
reduced pressure distillation by a rotary evaporator. The crude mass
was passed quickly through a purification columnwith ethyl acetate to
get highly pure (>98%) and crystalline compounds. The spectral data
of the compounds are given below:
2-phenyl-4a,5,6,7,8,8a-hexahydroquinoxaline (1, Scheme 1).
Brownish-yellow amorphous solid (206 mg, 97%); m. p.
135–136°C; IR (KBr) 3,415, 1,660, 1,536, 1,448, 1,294,
764 cm−1; 1H NMR (600 MHz, CDCl3) d 1.46–2.18 (m, 8H),
3.66 (br s, 1H), 3.77 (d, J  3.60 Hz, 1H), 7.42 (s, 1H), 7.48–7.50
(m, 2H), 7.86 (dd, J  7.56, 1.38 Hz, 2H), 8.39 (d, J  2.10 Hz, 1H);
13C NMR (150 MHz, CDCl3) 22.35, 22.66, 27.75, 28.07, 54.11,
54.21, 126.59, 128.77, 130.55, 136.12, 151.62, 155.44. Anal. Calcd
for C14H16N2: C, 79.21; H, 7.60; N, 13.20. Found: C, 79.09; H,
7.52; N, 13.11.
SCHEME 1 | Ultrasound-assisted on-water green synthesis of diverse benzopyrazines.
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2,3-diphenyl-4a,5,6,7,8,8a-hexahydroquinoxaline (2, Scheme 1).
Greenish-yellow crystalline solid (276 mg, 96%); m. p. 94–95°C; IR
(KBr) 3,312, 3,061, 2,930, 2,851, 1,665, 1,560, 1,489, 1,446, 1,240,
1,184, 1,077, 1,012, 758, 698 cm−1; 1H NMR (600MHz, CDCl3) d
1.48–1.85 (m, 8H), 3.84 (br s, 2H), 7.24–7.39 (m, 10H); 13C NMR
(150MHz, CDCl3) 22.51, 27.42, 55.01, 127.92, 128.01, 129.26,
138.29, 159.49. Anal. Calcd for C20H20N2: C, 83.30; H, 6.99; N, 9.71.
Found: C, 83.18; H, 6.87; N, 9.58.
2-Phenylquinoxaline (3, Scheme 1). Light brown crystalline
solid (194 mg, 94%); m. p. 77–79°C; IR (ν in cm−1): 1727, 1,538,
1,482, 1,303, 1,124, 1,027, 951, 760, 682, 550; 1H NMR (600 MHz,
CDCl3) δ 7.52–7.59 (m, 3H), 7.74–7.80 (m, 2H), 8.14 (d, J  8.16
Hz, 1H), 8.17 (d, J  8.22 Hz, 1H), 8.21 (d, J  7.62 Hz, 2H), 9.34
(s, 1H); 13C NMR (150 MHz, CDCl3) δ 127.57, 129.14, 129.16,
129.54, 129.65, 130.20, 130.28, 136.80, 141.60, 142.32, 143.37,
151.85. Anal. Calcd for C14H10N2: C, 81.53; H, 4.89; N, 13.58.
Found: C, 81.18; H, 4.87; N, 14.06.
6-Methoxy-2-phenylquinoxaline (4, Scheme 1): White
crystalline solid (217 mg, 92%); m. p. 75–77°C; IR (ν in cm−1):
1,616, 1,541, 1,508, 1,489, 1,456, 1,374, 1,314, 1,212, 1,117, 1,019,
827, 754, 687; 1H NMR (600 MHz, CDCl3) δ 3.90 (s, 3H), 7.30
(dd, J  8.95, 2.76 Hz, 1H), 7.35 (d, J  2.70 Hz, 1H), 7.43–7.49 (m,
3H), 7.90 (d, J  9.06 Hz, 1H), 8.07 (s, 1H), 8.08 (m, 1H), 9.08 (s,
1H); 13C NMR (150 MHz, CDCl3) δ 55.84, 106.91, 122.89, 127.52,
129.10, 129.12, 130.05, 137.02, 137.80, 140.76, 143.98, 151.95,
161.08. Anal. Calcd for C15H12N2O: C, 76.25; H, 5.12; N, 11.86.
Found: C, 77.01; H, 4.91; N, 12.13.
6-Chloro-2-phenylquinoxaline (5, Scheme 1): Light brown
crystalline solid (215 mg, 95%); m. p. 146–147°C; IR (ν in
cm−1): 1,699, 1,540, 1,481, 1,449, 1,315, 1,223, 1,132, 1,073,
958, 829, 756, 711, 687; 1H NMR (600 MHz, CDCl3) δ
7.47–7.51 (m, 3H), 7.61 (dd, J  8.85, 2.22 Hz, 1H), 7.98 (d,
J  8.82 Hz, 1H), 8.01–8.04 (m, 1H), 8.08 (d, J  2.16 Hz, 1H),
8.10–8.12 (m, 1H), 9.24 (s, 1H); 13C NMR (150 MHz, CDCl3) δ
127.54, 127.63, 129.24, 130.37, 130.46, 130.54, 130.57, 136.34,
140.12, 142.68, 143.44, 152.59. Anal. Calcd for C14H9ClN2: C,
69.86; H, 3.77; N, 11.64. Found: C, 70.23; H, 4.06; N, 10.88.
6-Nitro-2-phenylquinoxaline (6, Scheme 1): Pale yellow
crystalline solid (246 mg, 98%); m. p. 210–211°C; IR (ν in
cm−1): 1,616, 1,556, 1,522, 1,348, 1,316, 1,077, 851, 832, 791,
764, 691; 1H NMR (600 MHz, CDCl3) δ 7.52–7.55 (m, 3H),
8.16–8.21 (m, 3H), 8.47 (dd, J  9.12, 2.52 Hz, 1H), 8.95 (d,
J  2.46 Hz, 1H), 9.42 (s, 1H); 13C NMR (150 MHz, CDCl3) δ
123.79, 125.67, 127.95, 129.43, 131.19, 131.41, 135.64, 140.36,
144.93, 145.50, 147.47, 154.33. Anal. Calcd for C14H9ClN2: C,
69.86; H, 3.77; N, 11.64. Found: C, 70.23; H, 4.06; N, 10.88.
6-Nitro-2,3-di-p-tolylquinoxaline (7, Scheme 1): Yellow
crystalline solid (352 mg, 99%); m. p. 162–163°C; IR (ν in
cm−1): 1,521, 1,339, 1,182, 1,050, 978, 818, 723, 601, 545, 530;
1H NMR (600 MHz, CDCl3) δ 2.41 (s, 6H), 7.21 (d, J  7.86 Hz,
4H), 7.49 (t, J  7.80 Hz, 4H), 8.27 (d, J  9.12 Hz, 1H), 8.50–8.52
(m, 1H), 9.05 (d, J  2.46 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ
21.42, 21.43, 123.02, 125.54, 129.19, 129.74, 129.84, 130.61,
135.38, 135.43, 139.83, 139.87, 140.03, 143.56, 147.70, 155.70,
156.32. Anal. Calcd for C22H17N3O2: C, 74.35; H, 4.82; N, 11.82.
Found: C, 73.98; H, 4.53; N, 12.01.
2,3-Bis(4-fluorophenyl)-6-nitroquinoxaline (8, Scheme 1):
Yellowish solid (337mg, 93%); m. p. 157–159°C; IR (ν in cm−1):
1,599, 1,528, 1,512, 1,397, 1,341, 1,230, 1,163, 1,050, 978, 846, 726,
564; 1H NMR (600MHz, CDCl3) δ 7.11 (t, J  8.46 Hz, 4H),
7.56–7.60 (m, 4H), 8.29 (d, J  9.12 Hz, 1H), 8.55 (dd, J  9.12,
2.46 Hz, 1H), 9.06 (d, J 2.46 Hz, 1H); 13CNMR (150MHz, CDCl3)
δ 115.74, 115.89, 123.51, 125.54, 130.72, 131.81, 131.91, 131.97,
132.02, 133.95, 133.98, 134.02, 134.04, 139.92, 143.48, 148.01, 154.37,
154.97, 162.86, 164.61. Anal. Calcd for C20H11F2N3O2: C, 66.12; H,
3.05; N, 11.57. Found: C, 66.58; H, 3.07; N, 11.33.
3-Methyl-6-nitro-2-phenylquinoxaline (9, Scheme 1): Light
yellow crystalline solid (257 mg, 97%); m. p. 131–133°C; IR (ν
in cm-1): 1,519, 1,398, 1,328, 1,071, 1,003, 897, 818, 764, 741, 693,
588; 1HNMR (600MHz, CDCl3) δ 2.78 (s, 3H), 7.49 (t, J  1.56 Hz,
3H), 7.61 (d, J  5.58 Hz, 2H), 8.10–8.17 (m, 1H), 8.40–8.44 (m,
1H), 8.94 (s, 1H); 13C NMR δ (150MHz, CDCl3) 23.85, 12,211,
124.67, 127.73, 127.91, 127.93, 128.72, 128.99, 136.88, 138.82,
142.64, 155.32, 156.15. Anal. Calcd for C15H11N3O2: C, 67.92;
H, 4.18; N, 15.84. Found: C, 68.05; H, 4.10; N, 15.79.
2,3-Diphenylquinoxaline (10, Scheme 1): Colorless crystals
(271 mg, 96%); m. p. 118–121°C; IR (ν in cm−1): 1,665, 1,560,
1,489, 1,240, 1,184, 1,077, 1,012, 877, 807, 758, 698; 1H NMR
(600 MHz, CDCl3) δ 7.36–7.40 (m, 6H), 7.55 (m, 4H), 7.79 (dd,
J  4.86, 3.00 Hz, 2H), 8.21 (dd, J  4.86, 2.88 Hz, 2H); 13C NMR
(150 MHz, CDCl3) δ 128.30, 128.83, 129.24, 129.89, 129.98,
139.13, 141.27, 153.49. Anal. Calcd for C20H14N2: C, 85.08; H,
5.00; N, 9.92. Found: C, 84.97; H, 5.11; N, 10.02.
6-Nitro-2,3-diphenylquinoxaline (11, Scheme 1): Deep yellow
solid (321 mg, 98%); m. p. 182–184°C; IR (ν in cm−1): 1,520,
1,341, 1,188, 1,063, 1,024, 979, 698; 1HNMR (600 MHz, CDCl3) δ
7.38–7.46 (m, 6H), 7.57–7.60 (m, 4H), 8.31 (d, J  9.18 Hz, 1H),
8.54 (dd, J  2.46, 9.12 Hz, 1H), 9.09 (d, J  2.52 Hz, 1H); 13C
NMR (150 MHz, CDCl3) δ 123.30, 125.64, 128.47, 129.65, 129.84,
129.92, 130.77, 138.05, 138.12, 139.99, 143.59, 147.90, 155.70,
156.32. Anal. Calcd for C20H13N3O2: C, 73.38; H, 4.00; N, 12.84.
Found: C, 73.69; H, 4.06; N, 12.71.
Trypanocidal and Leishmanicidal (in vitro)
Evaluations
We used the promastigotes of L. mexicana (MHOM/MX/
ISETGS) clinical strain for the leishmanicidal growth
TABLE 1 | The yield, and atom economy in the synthesis of
benzopyrazines (1–11).
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inhibition assay. The clinical strain was initially isolated from a
patient suffering from diffuse cutaneous leishmaniasis. We
carried out the trypanocidal assay with the epimastigotes of
T. cruzi (MHOM/MX/1994/NINOA). The clinical strain was
originally isolated from a patient with the disease in the acute
phase for this assay. Schneider’s Drosophila medium,
supplemented with 10% fetal bovine serum, penicillin (100
IU/ml), and streptomycin (100 μg/ml), was used to culture
the parasites at 26°C. The antiprotozoal assays were carried
out in 96-well plates using dimethyl sulfoxide (DMSO) as the
carrier. The standard controls and the testing compounds were
solubilized in DMSO and diluted as required. All the
antiprotozoal assays were performed in duplicate. Aliquots of
100 µL of compound solution and 100 µL of culture medium
containing 10,000 Leishmania promastigotes or 20,000 T. cruzi
epimastigotes were combined to obtain concentrations of 50, 25,
12.5, 6.25, 3.125 μg/ml, and so on. Two first-line commercial
drugs nifurtimox (antichagasic drug) and miltefosine
(leishmanicidal drug), were used as positive controls. Only
the parasite-containing culture was used as the negative
control. The plates were incubated for 72 h at a temperature
of 26°C, and the antiprotozoal activity of the compounds was
determined by direct count of parasites in a Neubauer chamber
(Chan-Bacab et al., 2009). The IC50 values (the concentration
required to inhibit 50% of parasite growth were calculated (in µg/
mL) by probit analysis (Hernández-Núñez et al., 2009).
In Silico Molecular Docking Studies
We conducted the in silico molecular docking study following our
previously published procedure (Laskar et al., 2019). In brief, the
ligands were prepared with their corresponding assigned atoms types
and charges using ChemOffice 2015 as MOL files and converted to
PDB and PDBQT sequentially following a few steps utilizing open-
source and well-known graphic user interface software. We imported
the control drugs (positive controls) from ChemSpider as MOL
format; if not, control ligands were manually prepared from
scratch. Crystal structures of the four proteins 4YPF, 1S0J, 4K32,
TABLE 2 | IC50 (µM ± SD) of the benzopyrazine (1–11) against epimastigotes from
T. cruzi and promastigote from L. mexicana.
Compound L. mexicana (M378) T. cruzi (NINOA)
1 12.46 ± 0.62 37.85 ± 0.52
2 >100 >100
3 50.86 ± 1.02 >100








Miltefosine — 19.56 ± 0.61
Nifurtimox 9.32 ± 0.31 —
TABLE 3 | Molecular docking scores of the compound 1 and the standard controls with the biomolecular targets.








1 −6.7 −7.3 −6.3 −7.4
Miltefosine −4.7 −5.4 −4.9 −6.0
Nifurtimox −7.0 −7.8 −6.6 −7.5
aBinding affinity [kcal/mol].
4YPF: Crystal structure of T. cruzi Histidyl-tRNA synthetase in complex with quinolin-3-amine.
1S0J: Trypanosoma cruzi trans-sialidase in complex with MuNANA (Michaelis complex).
4K32: Crystal structure of geneticin bound to the leishmanial rRNA A-site.
6QDA: Leishmania major N-myristoyltransferase in complex with quinazoline inhibitor IMP-0000811.
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6QDA (biological targets in this study) were imported from RCSB
(Rose et al., 2011) (http://www.rcsb.org), a member of Worldwide
Protein Data Bank (wwPDB). The MOL formats of the ligands were
changed to PDB format by Avogadro software (Hanwell et al., 2012).
The ligands were saved in. pdb format and AutoDock4.
AutoDockTools 1.5.6, part of AutoDock4 (AD4), were used to
alter the ligands and receptors (proteins) from PDB to PDBQT
formats. PDBQT format provides the molecular structure
coordinate files, including atomic partial charges, atom types,
torsional flexibility information, etc. The ligand files (in.pdb form)
were loaded onto the AutoDockTools dashboard to detect torsion
root, rotatable bonds and add gasteiger charges for atomic charges, if
necessary. The receptor-binding sites were localized using the
Adaptive Poisson-Boltzmann Solver (APBS) plugin for surface
electrostatic calculation and Computed Atlas Surface Topology of
proteins (CASTp) for a pocket that void detection on the protein
surface (Liang et al., 1998). Binding site visualization was made
feasible by Schrödinger Maestro, AutoDock4, PyMOL, and other
FIGURE 2 | (A) The binding mode of the interactions between 1with T. cruziHistidyl-tRNA synthetase (PDB ID: 4YPF). (B) Results of the validation of 1 inside the T.
cruzi histidyl-tRNA synthetase active sites.
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software. (Morris et al., 2009; Seeliger and deGroot, 2010; Schrodinger
Release 2016-4, 2016; PyMOL Molecular Graphics System, 2015;
Pettersen et al., 2004). These software packages offer a complete
molecular viewer and graphic user interface, which are essential for
structure-based drug design and discovery. PDBQT structure formats
are compatible with AutoDock Vina (Trott and Olson, 2010), a
complementaryAD4molecular docking program, and are required to
run the docking simulations. We used the Schrödinger Maestro to
visualizing and preparing the PDB receptor and ligand conformation
files for docking. We uploaded the receptor files to the Maestro
workspace, and the binding site surface area was calculated using the
TaskTree search bar and selectingBinding SurfaceAreaAnalysis. The
resulting free energy binding affinities (in kcal/mol) were recorded as
docking scores. These scores were considered to evaluate the strength
of non-covalent interaction between different receptor-ligand
conformations. A conformer with the lowest energy and highest
cluster counts was regarded as the best ligand conformation that fits
the binding site. The structural analysis was effectuated in Schrödinger
FIGURE 3 | (A) The bindingmode of the interactions between 1with T. cruzi trans-sialidase (PDB ID: 1S0J). (B)Results of the validation of 1 inside the T. cruzi trans-
sialidase active sites.
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Maestrowas set to 1) visualize the formation and quantify distances of
H-bonds, π-π stacking interactions, and close contacts of each ligand
to the receptor of interest; 2) obtain images of ligand-receptor residue
interactions within the vicinity of the binding site, and 3) observe the
receptor surface homology through molecular dynamics simulation
(Haile, 1992). The in silico docking study evaluated miltefosine
and nifurtimox, leishmanicidal, and trypanocidal control drugs,
respectively.
RESULTS
Green Synthesis of Diverse Benzopyrazines
Ultrasound-assisted diversely substituted benzopyrazines were
synthesized, inserting a powerful sonicator probe into the reaction
mixture. For the diamine and dicarbonyl compounds, various
substituents based on electron-withdrawing or electron-donating
ability were tested to generalize the reaction. The nitro, chloro, on
FIGURE 4 | (A) The binding mode of the interactions between 1 with Leishmanial rRNA A-site (PDB ID: 4K32). (B) Results of the validation of 1 inside the
Leishmanial rRNA A-site active sites.
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the diamine represent strong and weak electron-withdrawing groups
(EWG), whereas the fused cyclohexyl and methoxy groups represent
mild and strong electron-donating groups (EDG). The ultimate goal
was to evaluate whether the presence of these functional groups
influences the nucleophilicity of the diamines. Similarly, the
dicarbonyls’ electrophilicity was varied by introducing p-nitro,
p-fluoro (EWG) or methyl (EDG) in the dicarbonyl system. The
overall yield of the products indicates that the presence of EWG or
EDG does not influence the reaction significantly, which in turn
supports the universality of this synthetic method. Based on the
available literature, this is the first example of synthesizing
benzopyrazines under this condition. Our method produced
FIGURE 5 | (A) The binding mode of the interactions between 1 with Leishmania major N-myristoyltransferase (PDB ID: 6QDA). (B) Results of the validation of 1
inside the Leishmania major N-myristoyltransferase active sites.
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excellent yields of the corresponding products (overall yield 92% or
more) in a very short period. The yield of the products and the atom
economy of the reactions are shown in Table 1. The range of atom
economy in the series varies from 76.92 to 88.89%, which
undoubtedly supports the greenness of the synthetic method.
Trypanocidal and Leishmanicidal
Evaluations (in vitro) of the
Benzopyrazines (1–11)
We used the promastigotes of L. mexicana (MHOM/MX/ISETGS)
clinical strain for the leishmanicidal growth inhibition assay. The
clinical strain was initially isolated from a patient suffering from
diffuse cutaneous leishmaniasis. We carried out the trypanocidal
assaywith the epimastigotes ofT. cruzi (MHOM/MX/1994/NINOA).
The clinical strain was originally isolated from a patient with the
disease in the acute phase for this assay. Schneider’s Drosophila
medium, supplemented with 10% fetal bovine serum, penicillin (100
IU/ml), and streptomycin (100 μg/ml), was used to culture the
parasites at 26 °C. Two commercial drugs, miltefosine, and
nifurtimox were used as standard controls. Compound 1
demonstrated good in vitro activity against both the strains with
comparable IC50 values with both the controls: miltefosine and
nifurtimox. Compounds 3 and 4 showed moderate IC50 values
against the L. mexicana (M378) strain (Table 2). The standard
biosecurity and institutional procedure were followed during the
experiment.
In Silico Molecular Docking of the
Compound 1
T. cruzi Histidyl-tRNA synthetase (PDB ID: 4YPF; Koh et al.,
2015) and T. cruzi trans-sialidase (PDB ID: 1S0J; Amaya et al.,
2004) are considered as two major biological drug targets for
American trypanosomiasis whereas Leishmanial rRNA A-site
(PDB ID: 4K32; Shalev et al., 2013) and Leishmania major
N-myristoyltransferase (PDB ID: 6QDA; Bell et al., 2020) are
considered as the major biomolecular drug targets for
leishmaniasis (Kelly et al., 2020). As shown in Table 2,
compound 1 showed comparable in vitro trypanocidal and
leishmanicidal activities with two standard commercial drugs;
therefore, we hypothesized the inhibition of the proteins as
mentioned earlier with compound 1. To validate our
hypothesis, we carried out extensive molecular docking studies
of compound 1 against the four proteins. The docking scores are
presented in Table 3. Docking interactions between compound 1
with the four proteins are shown in Figures 2–5.
In Silico Drug-likeness Determination
Drug-likeness indicates the possibility of a molecule
becoming a drug. Accordingly, a drug molecule should
have a balance of various physicochemical properties like
molecular weight, hydrogen bond donor, hydrogen bond
acceptor, total polar surface area, rotatable bond,
hydrophilicity, lipophilicity, hydrophobicity, lipophobicity,
bioavailability, half-life, etc. The druggability assessment of
all the eleven benzopyrazines was performed in compliance
with Lipinski’s rule of five (RO5) (Lipiniki et al., 1997;
Lipiniki et al., 2001; Lipinski, 2004). The druggability
parameters of the eleven benzopyrazines are shown in
TABLE 4 | Interactions between compound 1 with the four biomolecular targets (PDB IDs: 4YPF, 1S0J, 4K32 and 6QDA).
Receptor Binding site residue(s) Type of interactions Hydrophobic residues Docking scorea
4YPF HID168 π-π stacking GLU105, ILE106, GLN109, PRO125, TRP155, ARG165, GLU167, CYS365 −6.7
1S0J N/A Hydrophobic interaction ARG35, ARG53, ASN60, ARG93, ASP96, TYR113, TRP120, LEU176, GLU230,
TRP312, ARG314, TYR342
−7.3
4K32 Guanine 8 H-Bond U9, A39, A40, A41, G43 −6.3
6QDA HID 219, PHE232 π-π stacking VAL81, GLU82, ASP83, PHE88, ARG89, PHE90, SER330, LEU341 −7.4
aBinding affinity [kcal/mol].
4YPF: Crystal structure of T. cruzi Histidyl-tRNA synthetase in complex with quinolin-3-amine.
1S0J: Trypanosoma cruzi trans-sialidase in complex with MuNANA (Michaelis complex).
4K32: Crystal structure of geneticin bound to the leishmanial rRNA A-site.
6QDA: Leishmania major N-myristoyltransferase in complex with quinazoline inhibitor IMP-0000811.
FIGURE 6 | X-ray crystallographic structure (ORTEP) of Compound 2.
Thermal ellipsoids are shown with 50% probability.
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Table 4. Compound 1 shows the minimum miLogP value
(2.96) out of all the eleven analogs without having any
significant violations of druggability.
DISCUSSION
We have carried out an expeditious green synthesis of a series of
diversely substituted benzopyrazines with a high atom economy
using an ultrasonic probe. No catalyst and/or additive was used
during the reaction. The reaction was conducted in the greenest
solvent water and extracted with a recommended green solvent
ethyl acetate (McElroy et al., 2015). The reaction comprises a
nucleophilic addition of the 1,2-dicarbonyl compounds to the
diamines. A plausible mechanism may involve ultrasound-
assisted activation of the carbonyl groups and subsequent
attack of the lone pair of electrons of the amine groups due to
a negative electromeric (-E) effect. Eventually, the elimination of
two water molecules and subsequent ring-closure lead to the
formation of benzopyrazines with a high atom economy. Our
method, as described herein, complies with most of the green
chemistry principles by removing the use of hazardous solvent/
catalyst/additive/procedure (Bandyopadhyay and Banik, 2021).
All the reactions were carried out for 3 minutes to remove/reduce
the possibility of by-product formation as the reaction mixtures
became hot after sonication for an average of 3 minutes, and
undesired by-products might form.
Up-/downregulation of a specific enzyme(s) (proteins) is
associated with almost all diseases. Subsequently, appropriate
inhibition of upregulating disease-causing enzyme(s) (direct or
indirect) through enzyme-ligand interactions is considered an
effective strategy for treating the specific disease. The enzyme T.
cruzi histidyl-tRNAhelps the parasite to incorporate histidine during
its protein synthesis through aminoacylation reaction in a two-step
process. Accordingly, inhibition of this enzymewill stop the required
protein synthesis, which will kill the parasite (Pham et al., 2014).
Then again, T. cruzi trans-sialidase is amembrane-anchored enzyme
that helps the parasite to transfer sialic acids from the cellular surface
of the host to that of the parasite. As no known human analog of this
enzyme exists, T. cruzi trans-sialidase is considered a safe drug target
for Chagas’ disease (Miller and Roitberg, 2013). On the other hand,
the leishmanial ribosomal-RNA A-site is considered a suspected
binding site for the small molecule inhibitors, which can interfere
with translation processes in the course of protozoal protein
synthesis (Shalev et al., 2013). In addition, another enzyme
leishmania major N-myristoyltransferase has been reported as a
validated drug target in the treatment of leishmaniasis. This enzyme
acts as a biocatalyst in the co-translational N-terminalmyristoylation
reaction, which is essential in synthesizing a wide range of
pathogenic proteins (Bell et al., 2020). Based on these published
reports, the four proteins mentioned earlier were chosen as the
biological targets in the present study.
Developing new therapeutic agents to counter eukaryotic
pathogens is exceedingly challenging. Apart from the drug
discovery-related regular hassles, this particular effort needs to
balance two additional crucial factors: 1) the evolutionary
conservation of drug targets between the animal or insect
(host) and the microorganism and 2) the development of
strain-dependent drug resistance in the human body. Chagas’
disease wasmainly originated and confined to the Latin American
countries until a few decades ago; however, the epidemiology of
this life-threatening disease has been changing with time. An
increased number of cases have been identified in the
United States of America, Canada, and many other countries
from Europe, some parts of Africa, the Eastern Mediterranean,
and the Western Pacific regions. Currently, an estimated 75
million people are in the risk zone of this disease (Maheshwari
and Bandyopadhyay, 2021; World Health Organization, 2021).
In contrast, infection due to the protozoa Trypanosoma cruzi is
curable if appropriate treatment can be started soon after the infection.
Leishmaniasis, anothermajor vector-borne protozoal disease, has three
major types: visceral, cutaneous, and mucocutaneous. An estimated
700,000 to 1 million people become infected each year (Maheshwari
and Bandyopadhyay, 2021; World Health Organization, 2021).
Accordingly, there is a strong need for new drugs with higher
potency and far-ranging efficacy against trypanosome parasites
TABLE 5 | Validation† of drug-likeness of the benzopyrazines (1–11).
Compound miLogPa HBAb HBDc TPSAd RBe MWf Violation
1 2.96 2 0 24.73 1 212.30 0
2 4.62 2 0 24.73 2 288.39 0
3 3.41 2 0 25.78 1 206.25 0
4 3.44 3 0 35.02 2 236.27 0
5 4.06 2 0 25.78 1 240.69 0
6 3.34 5 0 71.61 2 251.25 0
7 5.91 5 0 71.61 3 355.40 1
8 5.34 5 0 71.61 3 363.32 1
9 3.56 5 0 71.61 2 265.27 0
10 5.08 2 0 25.78 2 282.35 1
11 5.01 5 0 71.61 3 327.34 1
†Molinspiration property engine v2018.10.
amiLogP: Moriguchi octanol-water partition coefficient, is based on quantitative structure-LogP relationships, by using topological indexes.
bHydrogen bond acceptor.
cHydrogen bond donor.
dTotal polar surface area.
eNumber of rotatable bonds.
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such as Leishmania and Trypanosoma. Our benzopyrazine 1 showed
comparable in vitro activity against both the protozoa (L. Mexicana
and T. cruzi) with IC50 values 12.46 and 37.85 µM respectively,
whereas the standard commercial drugs nifurtimox and
miltefosine have IC50 values 9.32 and 19.56 µM against L.
Mexicana and T. cruzi. Based on the observed similarities in
the IC50 values, we hypothesized the inhibitory activity of
benzopyrazine 1, which has been validated through
subsequent in silico protein-ligand interactions study. Two
other benzopyrazines 3 and 4 showed moderate to high IC50
values (against the L. mexicana (M378) strain (50.86 and
39.83 µM, respectively) (Table 2).
As has been mentioned earlier, the proteins T. cruzi Histidyl-
tRNA synthetase (PDB ID: 4YPF) and T. cruzi trans-sialidase
(PDB ID: 1S0J) are considered as two major biological
drug targets for Chagas’ disease, whereas Leishmanial
rRNA A-site (PDB ID: 4K32) and Leishmania major
N-myristoyltransferase (PDB ID: 6QDA) are considered as
the major biomolecular drug targets for leishmaniasis (Kelly
et al., 2020). Benzopyrazine 1 demonstrated better binding
affinity towards all the four proteins than the standard
control drug miltefosine and comparable docking scores
with another control drug nifurtimox (Table 3).
Benzopyrazine 1 binds the ARG156, ARG165, and HID158
residues of T. cruzi Histidyl-tRNA synthetase, ALA59,
VAL95, LEU176, and ASP96 residues of T. cruzi trans-
sialidase, forms salt-bridge with Leishmanial rRNA A-site,
and binds the PHE 232, HID 219, GLU82, SER330 residues of
the Leishmania major N-myristoyltransferase (Figures 2–5).
The binding sites, type of interactions, hydrophobic residues,
and docking scores of compound 1 with the four
biomolecular targets (PDB IDs: 4YPF, 1S0J, 4K32 and
6QDA) have been summarized in Table 4. Compound 1
showed a higher binding affinity with the proteins with
PDB IDs 6QDA and 1S0J (−7.4 and −7.3 kcal/mol,
respectively) than the biomolecular targets with PDB IDs
4K32 and 4YPF (−6.3 and −6.7, respectively). The protein-
ligand docking interactions of the co-crystallized ligands as
described in the protein data bank (PDB) have also been
conducted, and the results have been summarized in
Supplementary Table S1 (see Supplementary material).
Notably, for the protein with PDB ID 4YPF, compound 1
has a higher binding affinity (−6.7 kcal/mol) than the co-
crystallized ligand quinoline-3-amine (−5.8 kcal/mol). It is
worthy of mentioning that the cis-stereochemistry of the
5,6,7,8-tetrahydroquinoxaline ring-juncture (Compounds 1
and 2) was confirmed by X-ray crystallographic analysis of
compound 2. The X-ray crystallographic structure (ORTEP)
of Compound 2 is shown in Figure 6. The thermal ellipsoids
are shown with 50% probability. The asymmetric unit
comprises one molecule of compound 2 situated in a
general position. The X-ray parameters can be found in
Supplementary Table S2 (see Supplementary material).
Here it is essential to mention that the benzopyrazines 3 and 4
demonstratedmoderate leishmanicidal activity against L.mexicana
(M378) strain. In addition, the lead compound 1 showed good
leishmanicidal and trypanocidal activities (in vitro) against both L.
mexicana (M378) and T. cruzi (NINOA) strains compared to the
standard controls. The other eight analogs did not demonstrate
notable biological activity against any of the tested strains. This
observation indirectly supports the selective toxicity of 1, 3, and 4
against the pathogenic strains. If all compounds showed activity
against the parasites, this effect could be considered a toxic effect.
Finally, the drug-likeness of all the eleven benzopyrazine
derivatives has been determined following the RO5 (Lipiniski
et al., 2001). Seven out of eleven compounds did not show any
violations which support the drug-likeness of these molecules.
Benzopyrazines 1, 3, and 4 are in good agreement with the RO5
(Table 5). Based on the promising druglike-ness as shown in
Table 5, it is expected that the molecules should have good
pharmacokinetics and pharmacodynamics properties.
CONCLUSION
An expeditious green ultrasound-assisted one-pot procedure of
synthesizing benzopyrazines is reported. This newly developed
method satisfies many aspects of green chemistry and maintains
a high atom economy. No catalyst/support/additive/hazardous
solvents were used to accomplish the synthesis. Most of the
synthesized compounds possess drug-likeness and follow RO5. A
minor violation of RO5 was noticed for four out of eleven products.
Benzopyrazines 3 and 4 demonstrated moderate leishmanicidal
activity against L. mexicana (M378) strain. The selective lead
compound 1 showed good leishmanicidal, and trypanocidal
activities (in vitro) against both L. mexicana (M378) and T. cruzi
(NINOA) strains compared to the standard controls. The hypothesis
of binding of the lead benzopyrazine 1 to the active sites of the four
proteins (T. cruzi Histidyl-tRNA synthetase, T. cruzi trans-sialidase,
leishmanial rRNA A-site, and leishmania major
N-myristoyltransferase) responsible for Chagas’ disease and
leishmaniasis disease. As mentioned earlier, the inhibition of the
proteins with the compounds 1 has been validated by in silico
molecular docking studies. Accordingly, benzopyrazine 1, as
reported herein, may find its application in the future drug
development process against two major neglected tropical
diseases: Chagas’ disease and leishmaniasis.
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